advanced search

EXPERT VIEW

WEARABLE INJECTORS: CHOOSING & TESTING OPTIMAL ADHESIVES
EXPERT VIEW
Dr Neal Carty
WEARABLE INJECTORS: CHOOSING & TESTING OPTIMAL ADHESIVES
Neal Carty and Deepak Prakash highlight the importance of choosing and testing adhesives for optimal wearable drug delivery device performance.
PRIMARY PACKAGING FOR WEARABLE INJECTION DEVICES
EXPERT VIEW
Dominique Bauert
PRIMARY PACKAGING FOR WEARABLE INJECTION DEVICES
Dominique Bauert and Anil Kumar Busimi provide an overview of existing wearable injector solutions and new requirements, with a focus on the role of the primary packaging inside the devices.
THE CHALLENGES OF VERIFYING A WEARABLE INFUSOR
EXPERT VIEW
Michael Penman
THE CHALLENGES OF VERIFYING A WEARABLE INFUSOR
Michael Penman shows why it is important to verify body-worn infusor performance, highlighting the challenges and learnings from an example where Team Consulting was tasked with the design and verification of one such wearable device.
A QUICK GUIDE TO USABILITY FOR WEARABLE INJECTORS
EXPERT VIEW
Cory Costantino
A QUICK GUIDE TO USABILITY FOR WEARABLE INJECTORS
Cory Costantino and Lauren Fennelly list some typical steps a user might take while using wearable injectors, providing tips and points to note at each step, including design tips that might pre-empt potential interaction problems, and points to consider when conducting usability testing.
3D PRINTING DRUGS: LEARNING FROM THE PIONEERS
EXPERT VIEW
Jamie Clayton
3D PRINTING DRUGS: LEARNING FROM THE PIONEERS
Jamie Clayton reviews the potential of 3D printing as a pharmaceutical production method and looks at the associated implications for formulation development, focusing on powder-based printing. He examines what leading experts now understand about how to specify powder feeds for 3D printing.
COMPACTION SIMULATION / INDUSTRIAL PRESS CORRELATION: TWO CASE STUDIES
EXPERT VIEW
Dr Aline Moulin
COMPACTION SIMULATION / INDUSTRIAL PRESS CORRELATION: TWO CASE STUDIES
Aline Moulin and Lucile Kowalski examine two case studies comparing compaction simulation with industrial compression.
INDUSTRIALISATION OF INHALATION PRODUCTS: OVERCOMING HURDLES AT COMMERCIAL SCALE
EXPERT VIEW
Robin Heath
INDUSTRIALISATION OF INHALATION PRODUCTS: OVERCOMING HURDLES AT COMMERCIAL SCALE
Robin Heath discusses the typical challenges in scaling-up drug products from small-scale production to commercial manufacturing – and how these can be overcome.
CUSTOMISED INFUSION PUMPS: THE FUTURE OF SELF-ADMINISTRATION?
EXPERT VIEW
Shaul Eitan
CUSTOMISED INFUSION PUMPS: THE FUTURE OF SELF-ADMINISTRATION?
Shaul Eitan explores the challenges of home infusion and examines how customisation and connectivity could help provide a solution.
CONNECTIVITY RESTORING TRUST IN PHARMA COMMUNICATIONS
EXPERT VIEW
Napoleon Monroe
CONNECTIVITY RESTORING TRUST IN PHARMA COMMUNICATIONS
Napoleon Monroe analyses connectivity coverage at recent drug delivery conferences and, more broadly, in various publications, to evaluate the current direction, and explore the scope for connectivity to effect changes benefiting multiple stakeholders across a range of treatment categories.
USER-CENTRED DEVICE CONNECTIVITY
EXPERT VIEW
Mark Tunkel
USER-CENTRED DEVICE CONNECTIVITY
Mark Tunkel and Carolyn Rose discuss the benefits of taking a user-needs approach, and mapping the patient journey, in a connectivity strategy.
PUSHING THE BOUNDARIES OF INFUSION PUMP INTEROPERABILITY
EXPERT VIEW
Tim Frearson
PUSHING THE BOUNDARIES OF INFUSION PUMP INTEROPERABILITY
Interoperability is not a new concept for infusion pumps. But in many cases hospitals have been slow to embrace the full potential of connectivity. When is this likely to change? What will hospitals need when it does? And where should infusion pump manufacturers focus innovation efforts in the meantime? Tim Frearson considers the options.
SIMULATING STRESSFUL, EMERGENCY-USE SCENARIOS DURING USABILITY TESTS OF INJECTION DEVICES
EXPERT VIEW
Allison Strochlic
SIMULATING STRESSFUL, EMERGENCY-USE SCENARIOS DURING USABILITY TESTS OF INJECTION DEVICES
Allison Strochlic highlights the importance of simulating environments that are as realistic as possible when conducting usability tests of emergency-use injection devices, and provides case studies with examples of how to create more realistic tests.
MICROLITRE DOSING WITH PREFILLABLE SYRINGES – WHEN DOES A DEVICE MAKE SENSE?
EXPERT VIEW
Dr Gautam N Shetty
MICROLITRE DOSING WITH PREFILLABLE SYRINGES – WHEN DOES A DEVICE MAKE SENSE?
Gautam Shetty and Bernd Zeiss outline factors that need to be weighed when considering a device-based approach to microlitre injections.
PATIENT TOLERABILITY WITH HIGH-VISCOSITY, LARGE-VOLUME SUBCUTANEOUS INFUSIONS
EXPERT VIEW
Jennifer Estep
PATIENT TOLERABILITY WITH HIGH-VISCOSITY, LARGE-VOLUME SUBCUTANEOUS INFUSIONS
Jennifer King and Matthew J Huddleston discuss the advantages of subcutaneous drug delivery and how these have yet to be fully harnessed in currently marketed therapeutics.
AUTOMATING UNDER UNCERTAINTY – GOOD PRACTICES
EXPERT VIEW
Simon Drexler
AUTOMATING UNDER UNCERTAINTY – GOOD PRACTICES
Simon Drexler discusses lessons learned and good practices when dealing with uncertainty at the various stages of automation development for drug delivery device manufacturing.
THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT
EXPERT VIEW
David Belton
THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT
David Belton discusses the meaning of quality by design in novel respiratory drug delivery device development. He covers how, with more novel devices, prior knowledge may be insufficient for a standard FMEA-style risk analysis, and alternate science-based methods, such as functional mapping and knowledge scoring, can help in achieving QbD.
IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?
EXPERT VIEW
Dr Igor Gonda
IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?
Igor Gonda covers the field of nasal and pulmonary delivery of biologics, considers past failures and successes, and proposes answers to the challenges faced, from biological, biopharmaceutical and commercial standpoints.
HAZARDOUS DRUG HANDLING AND INVESTIGATIONAL DRUGS: LESSONS TO LEARN
EXPERT VIEW
Marino Kriheli
HAZARDOUS DRUG HANDLING AND INVESTIGATIONAL DRUGS: LESSONS TO LEARN
Marino Kriheli discusses the need for closed-system transfer devices when handling hazardous drugs, particularly as they relate to investigational drugs, not only as key to patient and healthcare practitioner safety, but also in the context of upcoming US regulation.
SIX TECHNIQUES FOR RAPID EARLY-STAGE MEDICAL DEVICE DEVELOPMENT
EXPERT VIEW
Stuart Curtis
SIX TECHNIQUES FOR RAPID EARLY-STAGE MEDICAL DEVICE DEVELOPMENT
Stuart Curtis runs through six techniques which, in his experience, are invaluable for accelerating the early development stages of drug delivery device design and can therefore be of great use when trying to accelerate a product’s time to market.
THE ROAD TO PREFILLED DEVICES IN NOVEL COMBINATION PRODUCTS
EXPERT VIEW
Lior Shtram
THE ROAD TO PREFILLED DEVICES IN NOVEL COMBINATION PRODUCTS
Lior Shtram discusses three approaches to delivering novel combination products – user-filled, user-loaded and prefilled – through the lens of sterilisation processes and requirements at the industrial manufacturing scale.
SAFE, CONVENIENT AND EFFICIENT: INDIVIDUALISING PREFILLED SYRINGES
EXPERT VIEW
Ursula Hahn
SAFE, CONVENIENT AND EFFICIENT: INDIVIDUALISING PREFILLED SYRINGES
Ursula Hahn discusses the value of individualised prefilled syringes and explains how small changes in design or components can make a huge difference for doctors, patients and pharmaceutical manufacturers alike.
HOW SAFETY FEATURES MAKE OR BREAK INFUSION PUMP DESIGN
EXPERT VIEW
Charlotte Harvey
HOW SAFETY FEATURES MAKE OR BREAK INFUSION PUMP DESIGN
Charlotte Harvey and Tim Frearson overview the safety systems required when designing an infusion pump system, with a focus on free-flow prevention, occlusion detection and air-in-line detection.
CONNECTIVITY USING CONSUMER TECHNOLOGY TO CREATE REAL VALUE FOR PATIENTS
EXPERT VIEW
Napoleon Monroe
CONNECTIVITY USING CONSUMER TECHNOLOGY TO CREATE REAL VALUE FOR PATIENTS
Napoleon Monroe presents the case for the C-Container, a collective term for a theoretical class of consumer product designed to work with various drug delivery combination products.
INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS
EXPERT VIEW
Douglas Cusato
INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS
With the increasing use of intravitreal injections of vascular endothelial growth factor inhibitors in the treatment of numerous serious ocular diseases, Douglas Cusato provides a detailed comparative analysis of the issues at play.
Top